Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis


Current price
0.79 USD -0.01 USD (-1.25%)
Last closed 0.78 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 61 917 364 USD
Yield for 12 month -30.70 %
21.11.2021 - 28.11.2021

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. Address: Azrieli Center, Holon, Israel, 5885849


WallStreet Target Price

4.67 USD

P/E ratio

Dividend Yield

3.38 %

Current Year

+7 500 000 USD

Last Year

+6 000 000 USD

Current Quarter

Last Quarter

Current Year

+6 525 000 USD

Last Year

+5 320 000 USD

Current Quarter

Last Quarter

Key Figures CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -34 007 248 USD
Operating Margin TTM -460.07 %
PE Ratio
Return On Assets TTM -25.83 %
PEG Ratio
Return On Equity TTM -47.44 %
Wall Street Target Price 4.67 USD
Revenue TTM 7 500 000 USD
Book Value 0.6 USD
Revenue Per Share TTM 0.086 USD
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield 3.38 %
Gross Profit TTM 6 525 000 USD
Earnings Share -0.37 USD
Diluted Eps TTM -0.37 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CGEN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 3.38 %
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.2462
Price Sales TTM 8.2556
Enterprise Value EBITDA -0.0564
Price Book MRQ 1.1722

Financials CGEN

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CGEN

For 52 weeks

0.53 USD 1.49 USD
50 Day MA 0.75 USD
Shares Short Prior Month 1 509 070
200 Day MA 0.89 USD
Short Ratio 6.34
Shares Short 1 353 533
Short Percent 1.53 %